TY - JOUR AU - García-Navarrete, Yarely Itzayana AU - Vallejo-Villalobos, María Fernanda AU - Olivares-Gazca, Jesús Mauricio AU - Cantero-Fortiz, Yahveth AU - León-Peña, Andrés A. AU - Olivares-Gazca, Juan Carlos AU - Murrieta-Álvarez, Iván AU - Ruiz-Delgado, Guillermo J. AU - Ruiz-Argüelles, Guillermo J. PY - 2019 TI - Primary thrombophilia XV: antithrombotic treatment of sticky platelet syndrome worldwide JF - Annals of Blood; Vol 4 (July 2019): Annals of Blood Y2 - 2019 KW - N2 - Background: Sticky platelet syndrome (SPS) is a common but under-recognized cause of thrombosis. Treatment with antiplatelet drugs results in a low re-thrombosis rate. The aim of this study is to analyze the treatment of persons with SPS in different parts of the world. Methods: Data from 43 publications describing 1,494 patients with SPS worldwide were analyzed. Data concerning treatment was available in 16 of these papers, and involving 332 patients. Results: Three hundred thirty two patients were treated with antiplatelet drugs; 303 were given solely aspirin and 29 received combinations with aspirin (heparin or coumadin), whereas two persons did not receive aspirin. The re-thrombosis rate for patients given antiplatelet drugs was 5/332 (1.5%) and only 3 patients died. Conclusions: Most patients with SPS are treated with antiplatelet drugs worldwide, the re-thrombosis rate is very low. Physicians worldwide are aware of the fact that the best treatment for persons with the SPS is the use of antiplatelet drugs. UR - https://aob.amegroups.org/article/view/5039